Rebecca is engaged in oncology health services and outcomes research as a Senior Scientist with the Institute for Technology Assessment, an attending oncologist specializing in gastrointestinal malignancies at Beth Israel Deaconess Medical Center (BIDMC) and an Instructor in Medicine at Harvard Medical School. Her current and past research support includes the PCORT fellowship, the Young Investigator’s Award from the American Society of Clinical Oncology, the Timely Special Opportunity Award from the Dana-Farber Cancer Institute, the NIH Loan Repayment Program and the Clinical Research Feasibility Fund Award from BIDMC. Recent awards include the Lee Lusted Prize for outstanding research from the Society for Medical Decision Making and the Clinical Research Award from the Eastern Cooperative Oncology Group.
Rebecca received a B.A in economics from Harvard, an MD with honors in research from Cornell University, and an MPH from Harvard. She completed her internal medicine residency at New York-Presbyterian Hospital and her Hematology/Oncology fellowship at BIDMC. She completed the NCI-funded post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT). Rebecca’s research goals are to improve oncology treatment decision making through better characterization of cancer patient outcomes, improved accuracy of clinical endpoints, assessment of the economic implications of cancer therapy and application of decision analysis tools.
In the Spring of 2011, Rebecca recorded a podcast entitled "Pathologic Complete Response and Toxicity Results from the STAR-01 Trial Evaluating the Addition of Oxaliplatin to Neodjuvant Chemoradiation for Locally Advanced Rectal Cancer" |
-
Chan, J. A., Stuart, K., Earle, C. C., Clark, J. W., Bhargava, P., Miksad, R., Blaszkowsky, L., Enzinger, P. C., Meyerhardt, J. A., Zheng, H., Fuchs, C. S. & Kulke, M. H. (2012). Prospective study of bevacizumab plus temozolomide in patients with
advanced neuroendocrine tumors.. J Clin Oncol, 30(24), 2963-2968.
-
Zhu, A. X., Abrams, T. A., Miksad, R., Blaszkowsky, L. S., Meyerhardt, J. A., Zheng, H., Muzikansky, A., Clark, J. W., Kwak, E. L., Schrag, D., Jors, K. R., Fuchs, C. S., Iafrate, A. J., Borger, D. R. & Ryan, D. P. (2011). Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer, 117(22), 5094-102.
[Online version]
-
Mahadevan, A., Miksad, R., Goldstein, M., Sullivan, R., Bullock, A., Buchbinder, E., Pleskow, D., Sawhney, M., Kent, T., Vollmer, C. & Callery, M. (2011). Induction gemcitabine and stereotactic body radiotherapy for locally
advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys, 81(4), e615-22.
[Online version]
-
Doherty, G. A., Miksad, R., Cheifetz, A. S. & Moss, A. C. (2011). Comparative cost-effectiveness of strategies to prevent postoperative
clinical recurrence of Crohn's disease. Inflamm Bowel Dis.
[Online version]
-
Kamo, N., Dandapani, S. V., Miksad, R., Houlihan, M. J., Kaplan, I., Regan, M., Greenfield, T. K. & Sanda, M. G. (2011). Evaluation of the SCA instrument for measuring patient satisfaction
with cancer care administered via paper or via the Internet. Ann Oncol, 22(3), 723-9.
[Online version]
|
